Teleflex (NYSE:TFX) Given Hold Rating at Needham & Company LLC

Teleflex (NYSE:TFX)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a note issued to investors on Friday, Benzinga reports.

A number of other analysts have also issued reports on TFX. Stephens lifted their target price on Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Royal Bank of Canada lifted their price objective on Teleflex from $260.00 to $275.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Truist Financial increased their target price on Teleflex from $247.00 to $255.00 and gave the company a “hold” rating in a research note on Monday, October 14th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $268.86.

Teleflex Trading Down 14.5 %

Shares of TFX opened at $201.02 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.58 and a quick ratio of 1.44. Teleflex has a 12 month low of $178.83 and a 12 month high of $257.85. The stock has a market cap of $9.47 billion, a PE ratio of 36.09, a P/E/G ratio of 2.13 and a beta of 1.16. The stock’s 50-day moving average is $240.17 and its two-hundred day moving average is $223.92.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.38 by $0.11. Teleflex had a net margin of 8.76% and a return on equity of 14.51%. The company had revenue of $764.40 million during the quarter, compared to the consensus estimate of $768.68 million. During the same quarter last year, the company earned $3.64 earnings per share. Teleflex’s revenue for the quarter was up 2.4% on a year-over-year basis. Equities analysts forecast that Teleflex will post 13.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Stuart A. Randle sold 2,674 shares of Teleflex stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $238.93, for a total value of $638,898.82. Following the completion of the transaction, the director now directly owns 5,496 shares of the company’s stock, valued at approximately $1,313,159.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.43% of the stock is currently owned by company insiders.

Institutional Trading of Teleflex

Several hedge funds have recently made changes to their positions in the stock. First Trust Direct Indexing L.P. lifted its stake in Teleflex by 6.2% in the first quarter. First Trust Direct Indexing L.P. now owns 1,254 shares of the medical technology company’s stock valued at $284,000 after buying an additional 73 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Teleflex in the 1st quarter valued at about $2,467,000. BNP Paribas Financial Markets boosted its stake in Teleflex by 54.2% during the 1st quarter. BNP Paribas Financial Markets now owns 61,268 shares of the medical technology company’s stock valued at $13,857,000 after purchasing an additional 21,533 shares during the period. Tokio Marine Asset Management Co. Ltd. boosted its stake in Teleflex by 6.2% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,451 shares of the medical technology company’s stock valued at $328,000 after purchasing an additional 85 shares during the period. Finally, Nordea Investment Management AB grew its position in Teleflex by 17.4% in the 1st quarter. Nordea Investment Management AB now owns 3,481 shares of the medical technology company’s stock worth $782,000 after purchasing an additional 517 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.